164 related articles for article (PubMed ID: 33375459)
1. Open Label Prospective Experience of Supplementation with a Fixed Combination of Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis.
Vikelis M; Dermitzakis EV; Vlachos GS; Soldatos P; Spingos KC; Litsardopoulos P; Kararizou E; Argyriou AA
J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33375459
[TBL] [Abstract][Full Text] [Related]
2. A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study.
Guilbot A; Bangratz M; Ait Abdellah S; Lucas C
BMC Complement Altern Med; 2017 Aug; 17(1):433. PubMed ID: 28854909
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
4. Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine.
Bagley CL; Rendas-Baum R; Maglinte GA; Yang M; Varon SF; Lee J; Kosinski M
Headache; 2012 Mar; 52(3):409-21. PubMed ID: 21929662
[TBL] [Abstract][Full Text] [Related]
5. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
[TBL] [Abstract][Full Text] [Related]
6. Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study.
Kinfe TM; Pintea B; Muhammad S; Zaremba S; Roeske S; Simon BJ; Vatter H
J Headache Pain; 2015; 16():101. PubMed ID: 26631234
[TBL] [Abstract][Full Text] [Related]
7. BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm.
Martinelli D; Arceri S; De Icco R; Allena M; Guaschino E; Ghiotto N; Bitetto V; Castellazzi G; Cosentino G; Sances G; Tassorelli C
Cephalalgia; 2022 Feb; 42(2):170-175. PubMed ID: 34404257
[TBL] [Abstract][Full Text] [Related]
8. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures.
Silberstein S; Lipton R; Dodick D; Freitag F; Mathew N; Brandes J; Bigal M; Ascher S; Morein J; Wright P; Greenberg S; Hulihan J
Headache; 2009 Sep; 49(8):1153-62. PubMed ID: 19719543
[TBL] [Abstract][Full Text] [Related]
9. Open label trial of coenzyme Q10 as a migraine preventive.
Rozen TD; Oshinsky ML; Gebeline CA; Bradley KC; Young WB; Shechter AL; Silberstein SD
Cephalalgia; 2002 Mar; 22(2):137-41. PubMed ID: 11972582
[TBL] [Abstract][Full Text] [Related]
10. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.
Lipton RB; Tepper SJ; Reuter U; Silberstein S; Stewart WF; Nilsen J; Leonardi DK; Desai P; Cheng S; Mikol DD; Lenz R
Neurology; 2019 May; 92(19):e2250-e2260. PubMed ID: 30996060
[TBL] [Abstract][Full Text] [Related]
11. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.
Dodick DW; Freitag F; Banks J; Saper J; Xiang J; Rupnow M; Biondi D; Greenberg SJ; Hulihan J;
Clin Ther; 2009 Mar; 31(3):542-59. PubMed ID: 19393844
[TBL] [Abstract][Full Text] [Related]
12. Onabotulinumtoxin-A treatment in Greek patients with chronic migraine.
Vikelis M; Argyriou AA; Dermitzakis EV; Spingos KC; Mitsikostas DD
J Headache Pain; 2016 Dec; 17(1):84. PubMed ID: 27640152
[TBL] [Abstract][Full Text] [Related]
13. Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: Japan Phase 2 Study.
Shibata M; Nakamura T; Ozeki A; Ueda K; Nichols RM
J Pain Res; 2020; 13():3531-3538. PubMed ID: 33408512
[TBL] [Abstract][Full Text] [Related]
14. SumaRT/Nap vs naproxen sodium in treatment and disease modification of migraine: a pilot study.
Cady R; O'Carroll P; Dexter K; Freitag F; Shade CL
Headache; 2014 Jan; 54(1):67-79. PubMed ID: 24021029
[TBL] [Abstract][Full Text] [Related]
15. Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab.
Ayer DW; Skljarevski V; Ford JH; Nyhuis AW; Lipton RB; Aurora SK
Headache; 2018 Sep; 58(8):1225-1235. PubMed ID: 30106172
[TBL] [Abstract][Full Text] [Related]
16. Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials.
Silberstein SD; Cohen JM; Yang R; Gandhi SK; Du E; Jann AE; Marmura MJ
J Headache Pain; 2021 Jan; 22(1):2. PubMed ID: 33413075
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
Stauffer VL; Dodick DW; Zhang Q; Carter JN; Ailani J; Conley RR
JAMA Neurol; 2018 Sep; 75(9):1080-1088. PubMed ID: 29813147
[TBL] [Abstract][Full Text] [Related]
18. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
Dodick DW; Silberstein SD; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
JAMA; 2018 May; 319(19):1999-2008. PubMed ID: 29800211
[TBL] [Abstract][Full Text] [Related]
19. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study.
Buse D; Manack A; Serrano D; Reed M; Varon S; Turkel C; Lipton R
Headache; 2012 Jan; 52(1):3-17. PubMed ID: 22106869
[TBL] [Abstract][Full Text] [Related]
20. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Lenz R; Wang Y; Cheng S; Hirama T; Mikol DD
Headache; 2019 Nov; 59(10):1731-1742. PubMed ID: 31612482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
